Endothelial dysfunction in patients with type 2 diabetes and the effects of thiazolidinedione antidiabetic agents

Journal of Diabetes and its Complications

Volumn 18, Issue 2, 2004, Pages 91-102

  Dandona, Paresh ^a,b   Aljada, Ahmad ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b Diabetes Endocrinology Center of Western New York   (United States)

Author keywords

Antiinflammatory activity; Endothelial dysfunction; Insulin resistance; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTIINFLAMMATORY AGENT; ATORVASTATIN; INSULIN SENSITIZING AGENT; MARKER; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; STATIN; TROGLITAZONE;

ANGIOGENESIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD FLOW; CELL DAMAGE; CELL FUNCTION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFECT; ENDOTHELIUM CELL; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; IN VITRO STUDY; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIA; ISCHEMIC HEART DISEASE; LONG TERM CARE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT; PRIORITY JOURNAL; RISK FACTOR; VASCULAR DISEASE;

CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLIDINEDIONES;

EID: 2142710075     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(02)00259-3     Document Type: Article

References (137)

1. Abdu T.A., Elhadd T., Pfeifer M., Clayton R.N. Endothelial dysfunction in endocrine disease. Trends in Endocrinology and Metabolism. 12:2001;257-265
2. Aljada A., Dandona P. Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism. 49:2000;147-150
3. Aljada A., Garg R., Ghanim H., Mohanty P., Dandona P. Troglitazone reduces intranuclear activator protein (AP-1) in mononuclear cells (MNC) and plasma matrix metalloproteinase-9 (MMP-9) concentration. Diabetes. 50(Suppl. 2):2001;A532
4. Aljada A., Garg R., Ghanim H., Mohanty P., Hamouda W., Assian E., Dandona P. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an anti-inflammatory action. Journal of Clinical Endocrinology and Metabolism. 86:2001;3250-3256
5. Aljada A., Ghanim H., Assian E., Dandona P. Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism. 51:2002;487-491
6. Aljada A., Ghanim H., Mohanty P., Kapur N., Dandona P. Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. Journal of Clinical Endocrinology and Metabolism. 87:2002;1419-1422
7. Aljada A., Ghanim H., Saadeh R., Dandona P. Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. Journal of Clinical Endocrinology and Metabolism. 86:2001;450-453
8. Aljada A., Saadeh R., Assian E., Ghanim H., Dandona P. Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. Journal of Clinical Endocrinology and Metabolism. 85:2000;2572-2575
9. Balletshofer B.M., Rittig K., Enderle M.D., Volk A., Macrker E., Jacob S., Matthaei S., Rett K., Haring H.U. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation. 101:2000;1780-1784
10. Baron A.D., Steinberg H.O. Endothelial function, insulin sensitivity, and hypertension. Circulation. 96:1997;725-726
11. Benson G.M., Grimsditch D.C., Vidgeon-Hart M., Lloyd A., Overend P., Smith S.A. Rosiglitazone reduces atherosclerosis in ApoE mice. Diabetes. 50(Suppl. 2):2001;. 323-PP
12. Berliner J.A., Navab M., Fogelman A.M., Frank J.S., Demer L.L., Edwards P.A., Watson A.D., Lusis A.J. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation. 91:1995;2488-2496
13. Brunzell J., Cohen B., Kreider M., Biswas N., Ratner R., Freed M., Marcovina S. Rosiglitazone favourably affects LDL-C and HDL C heterogeneity in type 2 diabetes. Diabetes. 50(Suppl. 2):2001;. 567-P
14. Caballero A.E., Arora A., Saouaf R., Lim S.C., Smakowski P., Park J.Y., King G.L., LoGerfo F.W., Horton E.S., Veves A. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 48:1999;1856-1862
15. Caballero A.E., Saouaf R., Lim S.C., Hamdy O., O'Conner C., Abue-lenin K., LoGerfo F.W., Horton E.S., Veves A. The effects of troglitazone on the endothelial function of micro- and macrocirculation in patients with early or late stage type 2 diabetes. Diabetes. 50(Suppl. 2):2001;. 600-P
16. Calles-Escandon J., Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocrine Reviews. 22:2001;36-52
17. Calver A., Collier J., Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. Journal of Clinical Investigation. 90:1992;2548-2554
18. Carr M.E. Diabetes mellitus: a hypercoagulable state. Journal of Diabetes and its Complications. 15:2001;44-54
19. Cartwright J.E., Whitley G.S., Johnstone A.P. Endothelial cell adhesion molecule expression and lymphocyte adhesion to endothelial cells: effect of nitric oxide. Experimental Cell Research. 235:1997;431-434
20. Charbonneau F. Use of measures of endothelial function to stratify risk. Canadian Journal of Cardiology. 17(Suppl. A):2001;18A-21A
21. Cheetham C., Collis J., O'Driscoll G., Stanton K., Taylor R., Green D. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. Journal of the American College of Cardiology. 36:2000;1461-1466
22. Chen N.G., Han X. Dual function of troglitazone in ICAM-1 gene expression in human vascular endothelium. Biochemical and Biophysical Research Communications. 282:2001;717-722
23. Cleland S.J., Petrie J.R., Small M., Elliott H.L., Connell J.M. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension. 35:2000;507-511
24. Cleland S.J., Petrie J.R., Ueda S., Elliott H.L., Connell J.M. Insulin-mediated vasodilation and glucose uptake are functionally linked in humans. Hypertension. 33:1999;554-558
25. Cohen R.A., Zitnay K.M., Haudenschild C.C., Cunningham L.D. Loss of selective endothelial cell vasoactive functions caused by hypercholesterolemia in pig coronary arteries. Circulation Research. 63:1988;903-910
26. Collins A.R., Meehan W.P., Kintscher U., Jackson S., Wakino S., Noh G., Palinski W., Hsueh W.A., Law R.E. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 21:2001;365-371
27. Collins A.R., Noh G., Hsueh W.A., Law R.E. PPARgamma ligands attenuate angiotensin-II accelerated atherosclerosis in male low density receptor deficient (LDLR-/-) mice. Diabetes. 50(Suppl. 2):2001;. 292-P
28. Cominacini L., Garbin U., Fratta Pasini A., Campagnola M., Davoli A., Foot E., Sighieri A.M., Lo Cascio V., Ferrannini E. Troglitazone reduces LDL oxidation and lowers E-selectin concentration in NIDDM patients. Diabetes. 47:1998;130-133
29. Cominacini L., Garbin U., Pastorino A.M., Campagnola M., Fratta Pasini A., Davoli A., Rigoni A., Lo Cascio V. Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells. Diabetologia. 40:1997;165-172
30. Cox D.A., Vita J.A., Treasure C.B., Fish R.D., Alexander R.W., Ganz P., Selwyn A.P. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation. 80:1989;458-465
31. Dandona P., Aljada A., Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia. 45:2002;924-930
32. Dandona P., Aljada A., Mohanty P., Ghanim H., Hamouda W., Assian E., Ahmad S. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? Journal of Clinical Endocrinology and Metabolism. 86:2001;3257-3265
33. Dandona P., James I.M., Newbury P.A., Woollard M.L., Beckett A.G. Cerebral blood flow in diabetes mellitus: evidence of abnormal cerebrovascular reactivity. British Medical Journal. 2:1978;325-326
34. Dandona P., James I.M., Woollard M.I., Newbury P., Beckett A.G. Instability of cerebral blood-flow in insulin-dependent diabetics. Lancet. 2:1979;1203-1205
35. Dandona P., Thusu K., Cook S., Snyder B., Makowski J., Armstrong D., Nicotera T. Oxidative damage to DNA in diabetes mellitus. Lancet. 347:1996;444-445
36. De Courten I., McCarty D., Zimmet P. The scale of the problem and future risks. Hitman G.A. Type 2 diabetes: prediction, prevention. 1999;17-36 Wiley, Chichester
37. de Dios S.T., Hannan K.M., Dilley R.J., Hill M.A., Little P.J. Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovasular endothelial cells. Journal of Diabetes and its Complications. 15:2001;120-127
38. De Mattia G., Bravi M.C., Costanzo A., Laurenti O., Cassone Faldetta M., Armiento A., De Luca O., Ferri C. Effects of insulin on in vitro vascular cell adhesion molecule-1 expression and in vivo soluble VCAM-1 release. Diabetologia. 42:1999;1235-1239
39. DeFronzo R.A., Bonadonna R.C., Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 15:1992;318-368
40. Devaraj S., Hirany S.V., Burk R.F., Jialal I. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clinical Chemistry. 47:2001;1974-1979
41. Devaraj S., Jialal I. Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type 2 diabetic patients. Free Radical Biology and Medicine. 29:2000a;790-792
42. Devaraj S., Jialal I. Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol supplementation. Circulation. 102:2000b;191-196
43. Donatelli M., Hoffmann E., Colletti I., Andolina G., Russo V., Bucalo M.L., Valenti T.M., Compagno V., Cataldo M.G., Morici M.L. Circulating endothelin-1 levels in type 2 diabetic patients with ischaemic heart disease. Acta Diabetologica. 33:1996;246-248
44. Drexler H., Zeiher A.M., Wollschlager H., Meinertz T., Just H., Bonzel T. Flow-dependent coronary artery dilatation in humans. Circulation. 80:1989;466-474
45. Egashira K., Inou T., Hirooka Y., Yamada A., Maruoka Y., Kai H., Sugimachi M., Suzuki S., Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. Journal of Clinical Investigation. 91:1993;29-37
46. Emoto M., Anno T., Sato Y., Tanabe K., Okuya S., Tanizawa Y., Matsutani A., Oka Y. Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes. Diabetes. 50:2001;1166-1170
47. Fath-Ordoubadi F., Beatt K.J. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation. 96:1997;1152-1156
48. Freed M., Fuell D., Menci L., Heise M., Goldstein B. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes. Diabetologia. 43(Suppl. 1):2000;A267
49. Fuell, D., Freed, M. I., Greenberg, A., Haffner, S., & Chen, H. (2001, June 20-23). Correlation of levels of non-traditional cardiovascular risk factors with demographic and disease variables in patients with type 2 diabetes mellitus. Poster presented at ENDO 83rd Annual Meeting, Denver, CO, USA.
50. Fukunaga Y., Itoh H., Doi K., Tanaka T., Yamashita J., Chun T.H., Inou M., Masatsugu K., Sawada N., Saito T., Hosoda K., Kook H., Ueda M., Nakao K. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides. Atherosclerosis. 158:2001;113-119
51. Garg R., Kumbkarni Y., Aljada A., Mohanty P., Ghanim H., Hamouda W., Dandona P. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension. 36:2000;430-435
52. Ghanim H., Garg R., Aljada A., Mohanty P., Kumbkarni Y., Assian E., Hamouda W., Dandona P. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. Journal of Clinical Endocrinology and Metabolism. 86:2001;1306-1312
53. Ghanim H., Mohanty P., Aljada A., Chowhan S., Tripathy D., Dandona P. Insulin reduces the pro-inflammatory transcription factor, activation protein-1 (AP-1), in mononuclear cells (MNC) and plasma matrix metalloproteinase-9 (MMP-9) concentration. Diabetes. 50(Suppl. 2):2001;A408
54. Goligorsky M.S., Chen J., Brodsky S. Workshop: endothelial cell dysfunction leading to diabetic nephropathy: focus on nitric oxide. Hypertension. 37:2001;744-748
55. Grover A., Padginton C., Wilson M.F., Sung B.H., Izzo J.L. Jr., Dandona P. Insulin attenuates norepinephrine-induced venoconstriction. An ultrasonographic study. Hypertension. 25:1995;779-784
56. Haffner S.M., Agostino R.D. Jr., Saad M.F., O'Leary D.H., Savage P.J., Rewers M., Selby J., Bergman R.N., Mykkanen L. Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). American Journal of Cardiology. 85:2000;1395-1400
57. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 106:2002;679-684
58. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine. 339:1998;229-234
59. Home P., Gubb J. RECORD Study Steering Committee and Investigators Rosiglitazone evaluated for cardiac outcomes and regulation of glycemia in diabetes (RECORD): a long-term cardiovascular outcome study. Diabetes. 51(Suppl. 2):2002;2003
60. Houghton A.R., Harrison M., Perry A.J., Evans A.J., Cowley A.J. Endogenous insulin and insulin sensitivity. An important determinant of skeletal muscle blood flow in chronic heart failure? European Heart Journal. 19:1998;476-480
61. Inoue I., Itoh H., Tanaka T., Chun T.H., Doi K., Fukunaga Y., Sawada N., Yamshita J., Masatsugu K., Saito T., Sakaguchi S., Sone M., Yamahara K., Yurugi T., Nakao K. Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-gamma. Arteriosclerosis, Thrombosis, and Vascular Biology. 21:2001;560-566
62. Johnstone M.T., Creager S.J., Scales K.M., Cusco J.A., Lee B.K., Creager M.A. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 88:1993;2510-2516
63. Kato K., Satoh H., Endo Y., Yamada D., Midorikawa S., Sato W., Mizuno K., Fujita T., Tsukamoto K., Watanabe T. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochemical and Biophysical Research Communications. 258:1999;431-435
64. Keen H., Jarrett R.J. The WHO multinational study of vascular disease in diabetes: 2. Macrovascular disease prevalence. Diabetes Care. 2:1979;187-195
65. Khandoudi N., Delerive P., Berrebi-Bertrand I., Buckingham R.E., Staels B., Bril A. Rosiglitazone, a peroxisome proliferator-activated receptor-(gamma), inhibits the Jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes. 51:2002;1507-1514
66. Kinlay S., Libby P., Ganz P. Endothelial function and coronary artery disease. Current Opinion in Lipidology. 12:2001;383-389
67. Kinlay S., Selwyn A.P., Libby P., Ganz P. Inflammation, the endothelium, and the acute coronary syndromes. Journal of Cardiovascular Pharmacology. 32(Suppl. 3):1998;S62-S66
68. Komatsu M., Kawagishi T., Emoto M., Yamada A., Morioka T., Okuno Y., Nishizawa Y. Insulin resistance is associated with vascular endothelial dysfunction in patients with type 2 diabetes. Diabetes. 50(Suppl. 2):2001;1918-PO
69. Koshiyama H., Shimono D., Kuwamura N., Minamikawa J., Nakamura Y. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 86:2001;3452-3456
70. Kuboki K., Jiang Z.Y., Takahara N., Ha S.W., Igarashi M., Yamauchi T., Feener E.P., Herbert T.P., Rhodes C.J., King G.L. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation. 101:2000;676-681
71. Laakso M., Edelman S.V., Brechtel G., Baron A.D. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. Diabetes. 41:1992;1076-1083
72. Law R.E., Goetze S., Xi X.P., Jackson S., Kawano Y., Demer L., Fishbein M.C., Meehan W.P., Hsueh W.A. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation. 101:2000;1311-1318
73. Lebovitz H.E., Banerji M.A. Insulin resistance and its treatment by thiazolidinediones. Recent Progress in Hormone Research. 56:2001;265-294
74. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 91:1995;2844-2850
75. Luscher T.F. Mack Forster Award Lecture. Review. The endothelium as a target and mediator of cardiovascular disease. European Journal of Clinical Investigation. 23:1993;670-685
76. Luvara G., Pueyo M.E., Philippe M., Mandet C., Savoie F., Henrion D., Michel J.B. Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: prevention by angiotensin II antagonism. Arteriosclerosis, Thrombosis, and Vascular Biology. 18:1998;1408-1416
77. Makimattila S., Liu M.L., Vakkilainen J., Schlenzka A., Lahdenpera S., Syvanne M., Mantysaari M., Summanen P., Bergholm R., Taskinen M.R., Yki-Jarvinen H. Impaired endothelium-dependent vasodilation in type 2 diabetes. Relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care. 22:1999;973-981
78. Manson J.E., Colditz G.A., Stampfer M.J., Willet W.C., Krolewski A.S., Rosner B., Arky R.A., Speizer F.E., Hennekens C.H. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Archives of Internal Medicine. 151:1991;1141-1147
79. Marx N., Bourcier T., Sukhova G.K., Libby P., Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 19:1999;546-551
80. McLenachan J.M., Williams J.K., Fish E.D., Ganz P., Selwyn A.P. Loss of flow mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation. 84:1991;1273-1278
81. McTernan P.G., Eggo M.C., Smith S.A., Barnett A.H., Kumar S. Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human subcutaneous adipocytes. Diabetes. 50(Suppl. 2):2001;1132-P
82. Minamikawa J., Tanaka S., Yamauchi M., Inoue D., Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 83:1998;1818-1820
83. Mohanty, P., Aljada, A., Ghanim, H., Tripathy, D., Syed, T., Hofmayer, D., & Dandona, P. (in press). Rosiglitazone suppresses intranuclear factor κB (NF-κB) and reactive oxygen species (ROS) generation in mononuclear cells (MNC) and plasma CRP, MCP-1 and PAI-1 and enhances vascular reactivity: evidence of a potent anti-inflammatory effect. Circulation.
84. phox subunit expression on mononuclear cells (MNC): evidence of a potent anti-inflammatory effect. Diabetes. 50(Suppl. 2):2001;276-OR
85. Mohanty P., Hamouda W., Garg R., Aljada A., Ghanim H., Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. Journal of Clinical Endocrinology and Metabolism. 85:2000;2970-2973
86. Murata T., Hata Y., Ishibashi T., Kim S., Hsueh W.A., Law R.E., Hinton D.R. Response of experimental retinal neovascularization to thiazolidinediones. Archives of Ophthalmology. 119:2001;709-717
87. Natali A., Toschi E., Sironi A.M., Camastra S., Ferrannini E. Effect of essential hypertension on endothelial function in type 2 diabetic patients. Diabetes. 50(Suppl. 2):2001;653-P
88. National Diabetes Data Group. (1995). Diabetes America (2nd ed.). NIH Publication no. 95-1468.
89. Neunteufl T., Katzenschlager R., Hassan A., Klaar U., Schwarzacher S., Glogar D., Bauer P., Weidinger F. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis. 129:1997;111-118
90. Nishikawa T., Edelstein D., Du X.L., Yamagishi S., Matsumara T., Kaneda Y., Yorek M.A., Beebe D., Oates P.J., Hammes H.P., Giardino I., Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 404:2000;787-790
91. Nordt T.K., Peter K., Bode C., Sobel B.E. Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells. Journal of Clinical Endocrinology and Metabolism. 85:2000;1563-1568
92. O'Brien S.F., Watts G.F., Playford D.A., Burke V., O'Neal D.N., Best J.D. Low-density lipoprotein size, high-density lipoprotein concentration, and endothelial dysfunction in non-insulin-dependent diabetes. Diabetes Medicine. 14:1997;974-978
93. Ohta M.Y., Nagai Y., Takamura T., Nohara E., Kobayashi K. Inhibitory effect of troglitazone on TNF-alpha-induced expression of monocyte chemoattractant protein-1 (MCP-1) human endothelial cells. Diabetes Research and Clinical Practice. 48:2000;171-176
94. Okouchi M., Okayama N., Omi H., Kato T., Akao M., Uranishi H., Shimizu M., Itoh M. Protective actions of pioglitazone and gliclazide on endothelial-neutrophil adherence and endothelial surface expression of ICAM-1 mediated by high concentration of insulin. Diabetes. 50(Suppl. 2):2001;658-P
95. Petrie J., Ueda S., Webb D.J., Elliott H.L., Connell J.M. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation. 93:1996;1331-1333
96. Pickup J.C., Mattock M.B., Chusney G.D., Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 40:1997;1286-1292
97. Rajavashisth T.B., Andalibi A., Territo M.C., Berliner J.A., Navab M., Fogelman A.M., Lusis A.J. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature. 344:1990;254-257
98. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607
99. Renier G., Desfaits A.C., Serri O. Effect of gliclazide on monocyte-endothelium interactions in diabetes. Journal of Diabetes and its Complications. 14:2000;215-223
100. Ross R. Atherosclerosis-an inflammatory disease. New England Journal of Medicine. 340:1999;115-126
101. Satoh H., Tsukamoto K., Hashimoto Y., Togo M., Hara M., Maekawa H., Isoo N., Kimura S., Watanabe T. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARgamma on vascular endothelial function. Biochemical and Biophysical Research Communications. 254:1999;757-763
102. Schachlinger V., Britten M.B., Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 101:2000;1899-1906
103. Serne E.H., Stehouwer C.D., ter Maaten J.C., ter Wee P.M., Rauwerda J.A., Donker A.J., Gans R.O. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation. 99:1999;896-902
104. Sidell R.J., Cole M.A., Draper N.J., Desrois M., Buckingham R.E., Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes. 51:2002;1110-1117
105. Sidhu J.S., Kaski J.C. Peroxisome proliferator activated receptor gamma: a potential therapeutic target in the management of ischaemic heart disease. Heart. 86:2001;255-258
106. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chineti G., Fruchart J.C., Najib J., Maclouf J., Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 393:1998;790-793
107. Stehouwer C.D., Nauta J.J., Zeldenrust G.C., Hackeng W.H., Donker A.J., den Ottolander G.J. Urinary albumin exretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 340:1992;319-323
108. Steinberg H.O., Brechtel G., Johnson A., Fineberg N., Baron A.D. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. Journal of Clinical Investigation. 94:1994;1172-1179
109. Steinberg H.O., Tarshoby M., Monestel R., Hook G., Cronin J., Johnson A., Bayazeed B., Baron A.D. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. Journal of Clinical Investigation. 100:1997;1230-1239
110. Storey A.M., Perry C.J., Petrie J.R. Endothelial dysfuntion in type 2 diabetes. British Journal of Diabetes and Vascular Diseases. 1:2001;22-27
111. Stuhlinger M.C., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., Reaven G.M., Tsao P.S. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. Journal of the American Medical Association. 287:2002;1420-1426
112. Sung B.H., Ching M., Izzo J. Jr., Dandona P., Wilson M.F. Insulin-mediated venodilation is impaired in patients with high cholesterol. Hypertension. 31:1998;1266-1271
113. Suwaidi J.A., Hamasaki S., Higano S.T., Nishimura R.A., Holmes D.R. Jr., Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation. 101:2000;948-954
114. Suzuki T., Honda H., Notoya Y., Arai K., Inamura T., Kanazawa M., Hayashi T., Moroe H., Kogo H. Enhancement of endothelium-derived hyperpolarizing factor (EDHF)-mediated relaxation in the renal artery isolated from short term hypercholesterolemic rabbits: effects of pioglitazone. Diabetes. 50(Suppl. 2):2001;. 1938-PO
115. Tan K.C., Ai V.H., Chow W.S., Chau M.T., Leong L., Lam K.S. Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 84:1999;3212-3216
116. Tan K.C., Chow W.S., Tam S.C., Ai V.H., Lam C.H., Lam K.S. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. Journal of Clinical Endocrinology and Metabolism. 87:2000;563-568
117. Taylor A.J., Kent S.M., Flaherty P.J., Coyle L.C., Markwood T.T., Vernalis M.N. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 106:2002;2055-2060
118. Ting H.H., Timimi F.K., Boles K.S., Creager S.J., Cranz P., Creager M.A. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. Journal of Clinical Investigation. 97:1996;22-28
119. Tooke J. The association between insulin resistance and endotheliopathy. Diabetes, Obesity and Metabolism. 1(Suppl. 1):1999;S17-S22
120. Ueda S., Petrie J.R., Cleland S.J., Elliott H.L., Connell J.M. Insulin vasodilatation and the "arginine paradox" Lancet. 351:1998;959-960
121. Ueda S., Petrie J.R., Cleland S.J., Elliott H.L., Connell J.M. The vasodilating effect of insulin is dependent on local glucose uptake: a double-blind, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism. 83:1998;2126-2131
122. Upritchard J.E., Sutherland W.H., Mann J.I. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care. 23:2000;733-738
123. Utriainen T., Makimattila S., Virkamaki A., Lindholm H., Sovijarvi A., Yki-Jarvinen H. Physical fitness and endothelial function (nitric oxide synthesis) are independent determinants of insulin-mediated blood flow in normal subjects. Journal of Clinical Endocrinology and Metabolism. 81:1996;4258-4263
124. Uusitupa M., Niskanen L., Sutonen O., Pyorala K. Hyperinsulinemia and hypertension in patients with newly diagnosed non-insulin-dependent diabetes. Diabetes and Metabolism. 13:1987;369-374
125. Vehkavaara S., Makimattila S., Schlenzka A., Vakkilainen J., Westerbacka J., Yki-Jarvinen H. Insulin therapy improves endothelial function in type 2 diabetes. Arteriosclerosis, Thrombosis, and Vascular Biology. 20:2000;545-550
126. Vogel R.A., Correti M.C., Plotnick G.D. Effect of a single high-fat meal on endothelial function in healthy subjects. American Journal of Cardiology. 79:1997;350-354
127. Walker A.B., Chattington P.D., Buckingham R.E., Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes. 48:1999;1448-1453
128. Watanabe Y., Sunayama S., Shimada K., Sawano M., Hoshi S., Iwama Y., Mokuno H., Daida H., Yamaguchi H. Troglitazone improves endothelial dysfunction in patients with insulin resistance. Journal of Atherosclerosis and Thrombosis. 7:2000;159-163
129. Watts G.F., O'Brien S.F., Silvester W., Millar J.A. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated, non-insulin-dependent diabetes mellitus: role of dyslipidaemia. Clinical Science (London). 91:1996;567-573
130. Williams S.B., Cusco J.A., Roddy M.A., Johnstone M.T., Creager M.A. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. Journal of the American College of Cardiology. 27:1996;567-574
131. Winkler G., Lakatos P., Salamon F., Nagy Z., Speer G., Kovacs M., Harmos G., Dworak O., Csch K. Elevated serum TNF-alpha level as a link between endothelial dysfunction and insulin resistance in normotensive obese patients. Diabetes Medicine. 16:1999;207-211
132. Xin X., Yang S., Kowalski J., Gerritsen M.E. Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. Journal of Biological Chemistry. 274:1999;9116-9121
133. Yoshimoto T., Naruse M., Nishikawa M., Naruse T., Tanabe A., Seki T., Imaki T., Demura R., Aikawa E., Demura H. Antihypertensive and vasculo- and renoprotective effects of pioglitazone in genetically obese diabetic rats. American Journal of Physiology. 272:1997;E989-E996
134. Yudkin J.S., Stehouwer C.D.A., Emeis J.J., Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arteriosclerosis, Thrombosis, and Vascular Biology. 19:1999;972-978
135. Yue T.L., Chen J., Bao W., Narayanan P.K., Bril A., Jiang W., Lysko P.G., Gu J.L., Boyce R., Zimmerman D.M., Hart T.K., Buckingham R.E., Ohlstein E.H. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation. 104:2001;2588-2594
136. Zeng G., Quon M.J. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. Journal of Clinical Investigation. 98:1996;894-898
137. Zimmet P., McCarthy D. The NIDDM epidemic: global estimates and projection: a look into the crystal ball. IDF Bulletin. 40:1995;8-16